Sophie E. Legge

This study identifies genetic variants differentially associated with schizophrenia and bipolar disorder using CC-GWAS, finding 19 loci with divergent effects and biological themes related to neuronal function.

This study quantifies pharmacogenomic effect sizes for psychiatric drugs, finding larger effects for proximal outcomes like bioavailability than distal outcomes like efficacy and toxicity.

This paper investigates how genetic liabilities shared and differentiating between schizophrenia and bipolar disorder relate to cognition and educational attainment using UK Biobank data.

This study identifies somatic copy number variants (sCNVs) in schizophrenia cases, revealing their contribution to risk and specific NRXN1 disruptions.

This study identifies neurogenic transcriptional programs linked to neuropsychiatric disorders and cognition using DLG2 knockout models and transcriptomic data.

This study identifies 33 genome-wide significant SNPs associated with cerebellar volume in 33,265 UK-Biobank participants, highlighting 21 candidate genes and genetic correlations with other brain structures.

This study conducts the largest genetic association analysis of psychotic experiences in the UK Biobank, identifying four genome-wide significant loci and showing shared genetic risk with schizophrenia, depression, bipolar disorder, and neurodevelopmental disorders.

The paper analyzes rare and common alleles in schizophrenia trios, identifying rare missense variants in SLC6A1 and confirming the role of neurodevelopmental disorder genes.